135 related articles for article (PubMed ID: 22956183)
1. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Marín LA; Díaz MG; San Miguel JF; Sanz RG
Ann Hematol; 2013 Jan; 92(1):97-100. PubMed ID: 22956183
[TBL] [Abstract][Full Text] [Related]
2. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma.
Puig N; Sarasquete ME; Alcoceba M; Balanzategui A; Chillón MC; Sebastián E; Díaz MG; San Miguel JF; García-Sanz R
Eur J Haematol; 2012 Oct; 89(4):328-35. PubMed ID: 22805350
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
Kara IO; Duman BB; Afsar CU
J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
[TBL] [Abstract][Full Text] [Related]
4. Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.
González D; González M; Alonso ME; López-Pérez R; Balanzategui A; Chillón MC; Silva M; García-Sanz R; San Miguel JF
Leukemia; 2003 Jun; 17(6):1051-7. PubMed ID: 12764368
[TBL] [Abstract][Full Text] [Related]
5. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
6. Quantitative comparison of multiple myeloma tumor contamination in bone marrow harvest and leukapheresis autografts.
Vescio RA; Han EJ; Schiller GJ; Lee JC; Wu CH; Cao J; Shin J; Kim A; Lichtenstein AK; Berenson JR
Bone Marrow Transplant; 1996 Jul; 18(1):103-10. PubMed ID: 8832002
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH; Willemse MJ; van der Schoot CE; Hählen K; van Wering ER; van Dongen JJ
Leukemia; 2002 May; 16(5):928-36. PubMed ID: 11986956
[TBL] [Abstract][Full Text] [Related]
8. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
9. Ficolled bone marrow is superior to bone marrow buffy coat for detection of minimal residual disease in multiple myeloma.
Bai Y; Chim CS
Hematology; 2019 Dec; 24(1):533-537. PubMed ID: 31280705
[TBL] [Abstract][Full Text] [Related]
10. Detection of T-cell receptor delta gene rearrangement in T-cell malignancies by clonal specific polymerase chain reaction and its application to detect minimal residual disease.
Chan DW; Liang R; Kwong YL; Chan V
Am J Hematol; 1996 Jul; 52(3):171-7. PubMed ID: 8756082
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
[TBL] [Abstract][Full Text] [Related]
12. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
[TBL] [Abstract][Full Text] [Related]
13. Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.
González D; Balanzategui A; García-Sanz R; Gutiérrez N; Seabra C; van Dongen JJ; González M; San Miguel JF
Leukemia; 2003 Jul; 17(7):1398-403. PubMed ID: 12835730
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients.
Kara IO; Sahin B; Paydas S; Cetiner S
Saudi Med J; 2004 Nov; 25(11):1587-92. PubMed ID: 15573184
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow trephine combined with immunohistochemistry is superior to bone marrow aspirate in follow-up of myeloma patients.
Joshi R; Horncastle D; Elderfield K; Lampert I; Rahemtulla A; Naresh KN
J Clin Pathol; 2008 Feb; 61(2):213-6. PubMed ID: 17526802
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease.
van der Velden VH; de Bie M; van Wering ER; van Dongen JJ
Haematologica; 2006 May; 91(5):679-82. PubMed ID: 16627258
[TBL] [Abstract][Full Text] [Related]
17. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
[TBL] [Abstract][Full Text] [Related]
18. Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma.
Compagno M; Mantoan B; Astolfi M; Boccadoro M; Ladetto M
Methods Mol Med; 2005; 113():145-63. PubMed ID: 15968100
[TBL] [Abstract][Full Text] [Related]
19. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells.
Fuhler GM; Baanstra M; Chesik D; Somasundaram R; Seckinger A; Hose D; Peppelenbosch MP; Bos NA
Exp Cell Res; 2010 Jul; 316(11):1816-28. PubMed ID: 20307537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]